Literature DB >> 6344895

Cardiovascular and platelet effects in man of BW 245C, a stable mimic of epoprostenol (PGI2).

M A Orchard, J M Ritter, G L Shepherd, P J Lewis.   

Abstract

1 BW 245C is a stable hydantoin prostaglandin analogue with a biological action similar to epoprostenol (PGI2). 2 Intravenous BW 245C (1,2 and 4 ng kg-1 min-1) produced a progressive increase in heart rate and pulse pressure in four healthy male volunteers. 3 These changes in heart rate and pulse pressure were accompanied by reduced ex vivo platelet aggregation to submaximal concentrations of ADP. 4 In man, BW 245C has a profile of action and potency similar to PGI2. However, it has a longer duration of action than PGI2.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6344895      PMCID： PMC1427716          DOI： 10.1111/j.1365-2125.1983.tb02083.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  5 in total

1.  Aggregation of blood platelets by adenosine diphosphate and its reversal.

Authors:  G V BORN
Journal:  Nature       Date:  1962-06-09       Impact factor: 49.962

2.  A double blind placebo controlled crossover study of prostacyclin in man.

Authors:  G A FitzGerald; L A Friedman; I Miyamori; J O'Grady; P J Lewis
Journal:  Life Sci       Date:  1979-08-20       Impact factor: 5.037

3.  Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.

Authors:  H Pickles; J O'Grady
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

4.  Prostaglandin influence on pulmonary intravascular leukocytic aggregation during cardiopulmonary bypass.

Authors:  P J Bolanowski; J Bauer; G Machiedo; W E Neville
Journal:  J Thorac Cardiovasc Surg       Date:  1977-02       Impact factor: 5.209

5.  Successful therapy of advanced arteriosclerosis obliterans with prostacyclin.

Authors:  A Szczeklik; R Nizankowski; S Skawinski; J Szczeklik; P Gluszko; R J Gryglewski
Journal:  Lancet       Date:  1979-05-26       Impact factor: 79.321
  5 in total
  5 in total

1.  Effects of a stable prostaglandin analogue, L-644,122, in healthy and hypertensive men.

Authors:  J M Ritter; J R Ludgin; L A Scharschmidt; R D Smith; M J Dunn
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.

Authors:  J O'Grady; A Hedges; B J Whittle; L A Al-Sinawi; Q A Mekki; C Burke; S G Moody; M J Moti; S Hassan
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

3.  The effect of a prostaglandin DP-receptor partial agonist (192C86) on platelet aggregation and the cardiovascular system in healthy volunteers.

Authors:  S J Gray; H Giles; J Posner
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

4.  Characterization of the inhibitory prostanoid receptors on human neutrophils.

Authors:  A Wheeldon; C J Vardey
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

5.  Prostanoid receptors involved in regulation of the beating rate of neonatal rat cardiomyocytes.

Authors:  Hakima Mechiche; Stanislas Grassin-Delyle; Arnaud Robinet; Pierre Nazeyrollas; Philippe Devillier
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.